Page: details2
• Targeting IL-6 trans-signalling: past, present and future prospects.
Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Nat Rev Immunol. (2023) Apr 17:1–16. doi: 10.1038/s41577-023-00856-y. PMID: 37069261; PMCID: PMC10108826.
• Blocking only the bad side of IL-6 in inflammation and cancer.
Stefan Rose-John ; Cytokine 148 (2021) 155690 https://doi.org/10.1016/j.cyto.2021.155690
• Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities.
Jürgen Scheller, Christoph Garbers, Stefan Rose-John: Seminars in Immunology 26 (2014) 2–12 http://dx.doi.org/10.1016/j.smim.2013.11.002
• Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.
Iain L Campbell 1, Maria Erta, Sue Ling Lim, Ricardo Frausto, Ulrike May, Stefan Rose-John, Jürgen Scheller, Juan Hidalgo. J Neurosciences. 2014 Feb 12;34(7):2503-13. doi: 10.1523/JNEUROSCI.2830-13.2014.
• A new anti-mesothelin antibody targets selectively the membrane-associated form.
Asgarov K, Balland J, Tirole C, Bouard A, Mougey V, Ramos D, Barroso A, Zangiacomi V, Jary M, Kim S, Gonzalez-Pajuelo M, Royer B, de Haard H, Clark A, Wijdenes J, Borg C. MAbs. 2017 Apr;9(3):567-577. doi:10.1080/19420862.2017.1288770.
• A plasmocyte selective monoclonal antibody (B-B4) recognises syndecan-1.
John Wijdenes etc All, British Journal of Haematology, 1996, 94, 318-323
• Treatment of Acute Graft-versus-Host disease with monoclonal antibody to IL-2 Receptor.
P. Hervé and John Wijdenes, Letters to the Editor, the Lancet, Nov 5, 1988, 1072-1073
Call today on +44 7771 641570 or email andy@mabdesigns.co.uk
Scan this code with an authenticator app, such as Authy or Google Authenticator, preferably on a different device, then type in the access code it shows below and click OK to check it has been set up correctly. Then save your profile and then when you sign in you will be prompted for an access code, open your authenticator to get the current value and type it in.